Danish malaria vaccine to secure Indian funding

A Danish researcher is developing a vaccine for malaria, which is only the second candidate ever within this field to go into phase III of clinical trials. At the moment he is in India presenting the research to potential partners.

Foto: Colourbox

So far only one potential malaria vaccine, developed by GlaxoSmithKline, has reached clinical trial phase III. But now a Danish developed vaccine candidate is on the verge of joining that exclusive company.

Behind the vaccine is senior researcher Michael Theisen from Statens Serum Institute (SSI), who has spent the last roughly 20 years driving research to the current stage, where a clarification of the ongoing phase II trials is expected within six months.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier